Stock Ratings / Health Care / EMBC / earnings

MOBI (46) CLPT (34) OFIX (55) TMCI (41) ⌘ Pro Terminal →

Embecta Corp. (EMBC) Next Earnings Date & Expected ±10.3% Move

$6.56 +1.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Embecta Corp. (EMBC) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (63% profit margin, 36% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $371.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EMBC)Realized 20D OHLCV Swing Band: ±10.3%

NEXT EST. WINDOW: Dec 29, 2026 (~57 DAYS)

Historical OHLCV Volatility ±10.3% Swing Band

±$0.68 Expected Swing

MODEL EARNINGS SETUP GAUGE

EMBC Quantitative Pre-Earnings Setup: 74/100

Trailing EPS: $1.68 • YoY Revenue Growth: -3.8%

Model Bullish Setup (74/100)Model Risk Weight (26/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-09-30	$1.08B	$95.4M	$182.4M	62.6%
FY 2024	2024-09-30	$1.12B	$78.3M	$19.9M	65.5%
FY 2023	2023-09-30	$1.12B	$70.4M	$67.7M	62.6%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating EMBC & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on EMBC
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EMBC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.31%⚡ TESTING RESISTANCE

2026-10-30O $6.55H $6.58L $6.20C $6.56VOL 830.9K

RES: $7.07SUP: $3.71SMA50: $5.74SMA200: $6.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EMBC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EMBC Butterfly Map → + Track EMBC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-15.0%/yr Implied 5Y Growth

vs. -3.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EMBC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EMBC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EMBC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EMBC)

Health Care Rank #58 of 1016 ⚔️ MOBI vs EMBC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EMBC vs. MOBI, CLPT, OFIX, TMCI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Embecta Corp. (EMBC) ranks #58 by composite RQD confidence (74/100, grade B) and #489 by equity capitalization ($371.7M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EMBC ACTIVE Embecta Corp.	B	74/100	3.9x	62.6%	35.5%	+1.55%	$371.7M	Benchmark Subject
MOBI Mobia Medical Inc.	D	46/100	—	—	—	-4.41%	$375.2M	/mobi-vs-embc →
CLPT ClearPoint Neuro Inc.	E	34/100	—	61.4%	-35.0%	+1.23%	$342.7M	/clpt-vs-embc →
OFIX Orthofix Medical Inc.	D+	55/100	—	68.8%	-12.2%	+1.99%	$417.1M	/ofix-vs-embc →
TMCI Treace Medical Concepts Inc.	D-	41/100	—	79.8%	-32.4%	+4.76%	$329.1M	/tmci-vs-embc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001872789

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Embecta Corp. (EMBC) reported GAAP revenue of $1.08B (-3.8% vs. FY2024 revenue of $1.12B , and -3.6% cumulative change since FY2023) , GAAP net income of $95.4M, operating cash flow of $191.7M, and free cash flow of $182.4M (+816.6% YoY). On the balance sheet, EMBC closed FY2025 with $1.06B in total assets against $1.35B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$1.08B	$95.4M	$191.7M	$182.4M	$1.06B	$1.35B
FY2024 (FY)	2024-09-30	$1.12B	$78.3M	$35.7M	$19.9M	$1.15B	$1.53B
FY2023 (FY)	2023-09-30	$1.12B	$70.4M	$67.7M	$67.7M	—	—

3. EMBC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EMBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Embecta Corp. (NASDAQ: EMBC) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $6.56 (+1.55% 1D, market cap $371.7M). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, EMBC ranks #58 in composite RQD confidence.

How does EMBC compare to MOBI and CLPT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), EMBC carries a Roarable B (74/100 RQD), trailing P/E of 3.9x, gross margin of 62.6%, and ROIC of 35.5%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $375.2M) and CLPT (ClearPoint Neuro Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $342.7M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EMBC?

Per EMBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001872789), Embecta Corp. generated $1.08B in revenue (-3.8% YoY), $95.4M in net income, and $182.4M in free cash flow against $1.06B in total assets and $1.35B in total debt. Key quantitative strengths: Strong cash generator (63% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EMBC trading relative to its 50-day, 200-day, and 52-week technical levels?

EMBC last traded at $6.56 (+1.55% on volume of 1,108,560 shares), positioning the stock +14.29% above its 50-day simple moving average ($5.74) and +1.86% above its 200-day simple moving average ($6.44). Across its 52-week range of $2.77 to $14.91, EMBC sits at the 31.2% percentile with a 14-day RSI of 52.2 (NEUTRAL RANGE) and an implied next-earnings move of ±10.3% ($5.88 to $7.24).